World
Close-up of various colorful pills and capsules on a black background.
Photo: David Peterson

Australian regulator warns after oesophagus tear from counterfeit weight‑loss peptide

The Therapeutic Goods Administration warned after a patient suffered an oesophageal tear from a counterfeit version of experimental peptide retatrutide, a drug not approved for use in Australia.

By SamacharDaily Editorial Team • • 1 min read

The Therapeutic Goods Administration (TGA) issued an alert after a patient was hospitalised with a torn oesophagus, having taken a counterfeit product believed to be the experimental weight‑loss peptide retatrutide.

Retatrutide has not received approval from the TGA or any overseas regulator and cannot be legally prescribed or sold in Australia, underscoring that any such product on the market is unlawful and potentially dangerous.

ALSO READ | Meghan Markle posts first UK family video, showing Harry, kids fishing and mud play

Why This Matters

The incident highlights the growing danger of unapproved, counterfeit weight‑loss products circulating in the market, exposing consumers to severe health risks. It underscores the TGA's role in safeguarding public health and the need for heightened vigilance among buyers of experimental therapies.

Reporting based on verified dispatches from The Guardian. View primary release ↗
Stay Connected
Follow SamacharDaily on Instagram

Visual explainers, infographics, and daily news briefings on your feed.

More in World